BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31721282)

  • 1. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.
    Sant'Antonio E; Guglielmelli P; Pieri L; Primignani M; Randi ML; Santarossa C; Rumi E; Cervantes F; Delaini F; Carobbio A; Betti S; Rossi E; Lavi N; Harrison CN; Curto-Garcia N; Gisslinger H; Gisslinger B; Specchia G; Ricco A; Vianelli N; Polverelli N; Koren-Michowitz M; Ruggeri M; Girodon F; Ellis M; Iurlo A; Mannelli F; Mannelli L; Sordi B; Loscocco GG; Cazzola M; De Stefano V; Barbui T; Tefferi A; Vannucchi AM
    Am J Hematol; 2020 Feb; 95(2):156-166. PubMed ID: 31721282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study.
    Riva N; Ageno W; Poli D; Testa S; Rupoli S; Santoro R; Lerede T; Piana A; Carpenedo M; Nicolini A; Ferrini PM; Tosetto A; ;
    J Thromb Haemost; 2015 Jun; 13(6):1019-27. PubMed ID: 25845412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
    Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
    Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.
    Görtzen J; Hunka LM; Vonnahme M; Praktiknjo M; Kaifie A; Fimmers R; Jansen C; Heine A; Lehmann J; Goethert JR; Gattermann N; Goekkurt E; Platzbecker U; Brossart P; Strassburg CP; Brummendorf TH; Koschmieder S; Wolf D; Trebicka J
    Medicine (Baltimore); 2016 May; 95(20):e3355. PubMed ID: 27196445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.
    Kaifie A; Kirschner M; Wolf D; Maintz C; Hänel M; Gattermann N; Gökkurt E; Platzbecker U; Hollburg W; Göthert JR; Parmentier S; Lang F; Hansen R; Isfort S; Schmitt K; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
    J Hematol Oncol; 2016 Mar; 9():18. PubMed ID: 26944254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.
    De Stefano V; Qi X; Betti S; Rossi E
    Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation.
    Wille K; Sadjadian P; Becker T; Kolatzki V; Horstmann A; Fuchs C; Griesshammer M
    Ann Hematol; 2019 Jan; 98(1):93-100. PubMed ID: 30155552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythrocytes from patients with myeloproliferative neoplasms and splanchnic venous thrombosis show greater expression of Lu/BCAM.
    Novitzky-Basso I; Spring F; Anstee D; Tripathi D; Chen F
    Int J Lab Hematol; 2018 Aug; 40(4):473-477. PubMed ID: 29756283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses.
    Debureaux PE; Cassinat B; Soret-Dulphy J; Mora B; Verger E; Maslah N; Plessier A; Rautou PE; Ollivier-Hourman I; De Ledinghen V; Goria O; Bureau C; Siracusa C; Valla D; Giraudier S; Passamonti F; Kiladjian JJ
    Blood Adv; 2020 Aug; 4(15):3708-3715. PubMed ID: 32777065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2V617F mutation prevalence on Chilean adults suffering from primary mesenteric and portal venous thromboses.
    González-Montero J; Del Valle-Batalla L; Castillo-Astorga R; Marín Valdés A; Conte Lanza G
    Int J Lab Hematol; 2020 Jun; 42(3):331-334. PubMed ID: 32154655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical approach to splanchnic vein thrombosis: risk factors and treatment.
    Riva N; Donadini MP; Dentali F; Squizzato A; Ageno W
    Thromb Res; 2012 Oct; 130 Suppl 1():S1-3. PubMed ID: 23026649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.
    Pieri L; Paoli C; Arena U; Marra F; Mori F; Zucchini M; Colagrande S; Castellani A; Masciulli A; Rosti V; De Stefano V; Betti S; Finazzi G; Ferrari ML; Rumi E; Ruggeri M; Nichele I; Guglielmelli P; Fjerza R; Mannarelli C; Fanelli T; Merli L; Corbizi Fattori G; Massa M; Cimino G; Rambaldi A; Barosi G; Cazzola M; Barbui T; Vannucchi AM
    Am J Hematol; 2017 Feb; 92(2):187-195. PubMed ID: 27880982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.
    Finazzi G; De Stefano V; Barbui T
    Blood Cancer J; 2018 Jun; 8(7):64. PubMed ID: 29946154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry.
    Ageno W; Riva N; Schulman S; Beyer-Westendorf J; Bang SM; Senzolo M; Grandone E; Pasca S; Di Minno MN; Duce R; Malato A; Santoro R; Poli D; Verhamme P; Martinelli I; Kamphuisen P; Oh D; D'Amico E; Becattini C; De Stefano V; Vidili G; Vaccarino A; Nardo B; Di Nisio M; Dentali F
    JAMA Intern Med; 2015 Sep; 175(9):1474-80. PubMed ID: 26168152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Visceral Vein Thrombosis of Myeloproliferative Neoplasm --Review].
    Zhang X; Yang J; Hao HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1627-1630. PubMed ID: 36208278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated splanchnic vein thrombosis: Clinical implications and management considerations.
    Cohen O; Caiano LM; Levy-Mendelovich S
    Thromb Res; 2024 Feb; 234():75-85. PubMed ID: 38183815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splanchnic vein thrombosis in myeloproliferative neoplasms.
    Sekhar M; McVinnie K; Burroughs AK
    Br J Haematol; 2013 Sep; 162(6):730-47. PubMed ID: 23855810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
    Alvarez-Larrán A; Pereira A; Magaz M; Hernández-Boluda JC; Garrote M; Cuevas B; Ferrer-Marín F; Gómez-Casares MT; García-Gutiérrez V; Mata-Vázquez MI; Turon F; Hernandez-Gea V; Arellano-Rodrigo E; Cervantes F; García-Pagán JC;
    Ann Hematol; 2020 Apr; 99(4):791-798. PubMed ID: 32086587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype.
    Beleva EA
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.